Myriad Genetics, Inc. (NASDAQ:MYGN) VP Richard M. Marsh sold 13,759 shares of the business’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $36.25, for a total value of $498,763.75. Following the transaction, the vice president now directly owns 136,385 shares of the company’s stock, valued at approximately $4,943,956.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Myriad Genetics, Inc. (NASDAQ:MYGN) traded down $0.26 during trading on Tuesday, hitting $35.79. The stock had a trading volume of 1,073,954 shares, compared to its average volume of 567,490. Myriad Genetics, Inc. has a one year low of $15.15 and a one year high of $37.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06. The firm has a market capitalization of $2,500.00, a P/E ratio of 24.18, a P/E/G ratio of 2.29 and a beta of 0.24.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings data on Tuesday, November 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.05. Myriad Genetics had a return on equity of 9.54% and a net margin of 13.28%. The company had revenue of $190.20 million during the quarter, compared to the consensus estimate of $183.52 million. During the same quarter in the prior year, the firm posted $0.23 earnings per share. The firm’s revenue was up 7.2% compared to the same quarter last year. equities research analysts predict that Myriad Genetics, Inc. will post 1.05 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in MYGN. Dimensional Fund Advisors LP boosted its holdings in Myriad Genetics by 29.8% in the second quarter. Dimensional Fund Advisors LP now owns 3,430,216 shares of the company’s stock valued at $88,636,000 after acquiring an additional 787,396 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in Myriad Genetics by 98.2% in the third quarter. Wells Fargo & Company MN now owns 844,339 shares of the company’s stock valued at $30,548,000 after acquiring an additional 418,335 shares during the last quarter. PDT Partners LLC bought a new stake in Myriad Genetics in the second quarter valued at approximately $8,481,000. Northern Trust Corp boosted its holdings in Myriad Genetics by 31.1% in the second quarter. Northern Trust Corp now owns 1,292,588 shares of the company’s stock valued at $33,400,000 after acquiring an additional 306,276 shares during the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new stake in Myriad Genetics in the third quarter valued at approximately $9,083,000.

Several brokerages have commented on MYGN. Barclays reissued a “hold” rating and set a $30.00 target price on shares of Myriad Genetics in a research note on Monday, January 8th. BTIG Research began coverage on Myriad Genetics in a research note on Friday, January 5th. They set a “buy” rating and a $41.00 target price for the company. Stephens set a $45.00 target price on Myriad Genetics and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Zacks Investment Research downgraded Myriad Genetics from a “strong-buy” rating to a “hold” rating in a research note on Friday, December 15th. Finally, ValuEngine downgraded Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the company’s stock. Myriad Genetics has a consensus rating of “Hold” and a consensus price target of $30.09.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2018/01/16/myriad-genetics-inc-mygn-vp-sells-498763-75-in-stock.html.

Myriad Genetics Company Profile

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.